Document is current

Documents that mention this clinical trial

354 Pulling the lever on all fronts: ICT01, a g9d2 T cell-activating monoclonal antibody, in combination with Venetoclax and 5-Azacytidine as a novel combination therapy for AML
https://doi.org/10.1136/jitc-2022-sitc2022.0354

641 ICT01 and pembrolizumab in combination elicit deep and durable responses in heavily pretreated patients with urothelial cell carcinoma: interim results from study EVICTION
https://doi.org/10.1136/jitc-2024-sitc2024.0641

687 Enhancement of anti-tumor immunity by ICT01: a novel g9d2 T cell-activating antibody targeting butyrophilin-3A (BTN3A)
https://doi.org/10.1136/jitc-2020-sitc2020.0687

Therapeutic avenues for γδ T cells in cancer
https://doi.org/10.1136/jitc-2023-007955

715 ICT01 plus low dose SC IL-2 produces a robust anti-tumor immune activation in advanced cancer patients (EVICTION-2 Study)
https://doi.org/10.1136/jitc-2023-sitc2023.0715

528 Correlation of baseline circulating Vg9Vd2 T cell counts and pharmacodynamic activity of ICT01 in cancer patients: preliminary results from EVICTION and a novel patient enrichment strategy
https://doi.org/10.1136/jitc-2021-sitc2021.528

720 Enhancing the anti-tumor immunity and therapeutic potential of ICT01, a butyrophilin3A-targeted, γ9δ2 T cell-activating monoclonal antibody, with low dose IL-2 in patients with advanced solid tumors: The EVICTION-2 trial
https://doi.org/10.1136/jitc-2022-sitc2022.0720

3 Butyrophilin-3a is expressed in multiple solid tumors: translational research supporting the EVICTION study with ICT01, an anti-BTN3A mAb activating Vg9Vd2 T-Cells
https://doi.org/10.1136/jitc-2020-sitc2020.0003

Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies
https://doi.org/10.1136/jitc-2023-007981

316 EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A
https://doi.org/10.1136/jitc-2020-sitc2020.0316

692 ICT01 and pembrolizumab in combination elicit deep and durable responses in heavily pretreated patients with refractory melanoma: interim results from study EVICTION
https://doi.org/10.1136/jitc-2024-sitc2024.0692

563 ICT01, an anti-BTN3A mAb, and NL-201, an alpha-independent IL-2/IL-15 agonist, combine to elicit a potent anti-tumor response by synergistically stimulating Vg9Vd2 T cell activation and proliferation
https://doi.org/10.1136/jitc-2021-sitc2021.563

1307 ICT01, a γ9δ2 T-cell-activating mAb, in combination with pembrolizumab elicits deep and durable responses in second-line patients with primary refractory melanoma: Results from EVICTION study
https://doi.org/10.1136/jitc-2025-sitc2025.1307

EVICTION study: ICT01, an anti-Butyrophilin 3A monoclonal antibody activating γ9δ2 T cells in combination with pembrolizumab in checkpoint inhibitor refractory melanoma.
https://doi.org/10.1200/jco.2024.42.16_suppl.9534

503 Clinical activity of ICT01, an anti-BTN3A-targeted, γ9δ2-activating mAb, alone and in combination with pembrolizumab in patients with advanced/refractory solid tumors: EVICTION trial
https://doi.org/10.1136/jitc-2021-sitc2021.503

442 ICT01, an anti-BTN3A mAb that activates Vg9Vd2 T cells, plus interleukin-2: a potent and promising combination for cancer immunotherapy
https://doi.org/10.1136/jitc-2020-sitc2020.0442